The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020.

https://www.pfizer.com/news/press-re...vid-19-vaccine

Poslato sa ultra moderne pisaće mašine Note X

............ Ż\_(ツ )_/Ż.............